Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $55.35, for a total value of $608,850.00. Following the completion of the transaction, the chairman now owns 48,014 shares in the company, valued at approximately $2,657,574.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at 46.76 on Friday. The stock has a 50 day moving average of $52.52 and a 200 day moving average of $46.92. Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. The company has a market cap of $5.80 billion, a PE ratio of 224.81 and a beta of 3.14.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.03. The firm had revenue of $104.15 million for the quarter, compared to analysts’ expectations of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm’s quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.47) EPS. Equities analysts expect that Ionis Pharmaceuticals, Inc. will post ($0.02) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) Chairman Sells 11,000 Shares of Stock” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/12/ionis-pharmaceuticals-inc-ions-chairman-sells-608850-00-in-stock-updated-updated.html.
Several equities research analysts have issued reports on the company. BMO Capital Markets restated an “outperform” rating and set a $59.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, April 26th. Stifel Nicolaus increased their target price on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research report on Wednesday. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, July 5th. Leerink Swann restated an “outperform” rating and set a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $47.13.
A number of hedge funds have recently made changes to their positions in IONS. Dimensional Fund Advisors LP increased its stake in shares of Ionis Pharmaceuticals by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 196,812 shares of the company’s stock worth $10,014,000 after buying an additional 26,496 shares in the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth about $1,342,000. Teachers Retirement System of The State of Kentucky increased its stake in shares of Ionis Pharmaceuticals by 6.3% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 111,862 shares of the company’s stock worth $5,690,000 after buying an additional 6,658 shares in the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Ionis Pharmaceuticals by 0.4% in the second quarter. Parametric Portfolio Associates LLC now owns 100,250 shares of the company’s stock worth $5,100,000 after buying an additional 387 shares in the last quarter. Finally, Advisor Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 7.8% in the second quarter. Advisor Group Inc. now owns 9,733 shares of the company’s stock worth $475,000 after buying an additional 708 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
What are top analysts saying about Ionis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals Inc. and related companies.